A consortium funded by the National Institutes of Health (NIH) has unveiled the most comprehensive map of somatic mosaicism ...

Estuary Biotherapeutics Inc. has launched with $103 million in total committed financing that will support advancement of the ...

Impaired brain-derived neurotrophic factor (BDNF)-TrkB signaling has been implicated in a range of neurological and neuropsychiatric disorders. Researchers from Pangea Bio reported the development of ...

Expression Therapeutics Inc. has been awarded a Small Business Innovation Research (SBIR) phase II grant of over $2 million by the NIH’s National Cancer Institute to advance ET-501, its ...

Revolution Medicines Inc.’s KRAS inhibitor, Rasonque (daraxonrasib), received a thumbs-up from the EMA’s Committee for ...

Estuary Biotherapeutics Inc. emerged from stealth with a $93 million series A financing led by RA Capital Management to develop gene therapies to treat autosomal dominant polycystic kidney disease ...

T cells as potent killers of small-cell lung cancer, with their genetic signature potentially revealing patients who could ...

The complexity of osteoarthritis (OA) pain and the limitations associated with long-term opioid therapy have prompted interest in alternative analgesic strategies. Researchers at the Spanish National ...

Life sciences investors are raising billions of dollars in fresh capital, with a cluster of new funds and acquisition vehicles positioning specialist firms for more biotech company formation and ...

Following ongoing deals with Bristol Myers Squibb Co. and Eli Lilly and Co., AI and machine learning firm Insitro Inc. has ...

Researchers from the University of Wisconsin-Madison previously developed a tumor-selective alkyl phosphocholine analogue (NM-600) for radiopharmaceutical therapy of triple-negative breast cancer ...

Eikon Therapeutics Inc. has submitted an IND application to the FDA seeking to evaluate EIK-1006 for the treatment of advanced metastatic prostate cancer.